semaglutide st. petersburg Safe, At-Home Weight Loss Injections in Home | REVO Weight Loss

Over 61% of healthcare providers prefer GLP-1 drugs due to cardiovascular risk reduction benefits, impacting nearly 32% of high-risk patients globally

A Mounjaro, which uses the same ingredient (tirzepatide) and is made by the same company (Eli Lilly), is for people with diabetes

In a Phase 2 trial published in the New England Journal of Medicine in 2023, participants lost up to 24.2% of their body weight over 48 weeks

For patients, clinicians, and health systems alike, the arrival of an effective, convenient, and potentially affordable oral GLP-1 agonist represents a major change that could redefine how obesity is treated across the globe

Reduce appetite and food cravings